olivLaw · US equity research
SELLAS Life Sciences Group, Inc. SLS
Pharmaceutical Preparations · SIC 2834 · Vertical: Pharmaceutical Preparations (SIC 2834)
SELLAS Life Sciences Group is a late-stage biopharmaceutical company developing the GPS immunotherapy and the CDK9 inhibitor SLS009 for cancer, mainly acute myeloid leukemia. The company faces two key moments: the final analysis of the Phase 3 REGAL trial, triggered by the 80th event, and topline data from the Phase 2 SLS009 study, expected in the fourth quarter of 2026. As of June 30, 2026 it reported cash of $138.3 million.
At the close of 04 Nov 2026, SELLAS Life Sciences Group, Inc. (SLS) stock was 9.14 USD (+3.04% on the day), with market capitalisation 1.8 bn USD, beta 1.08, 52-week range 1.39–15.46 USD. Latest reported quarter (Q2 2026): net income of -9.6 m USD, diluted EPS -0.05 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 38.3
- weak (30–45)
- Bollinger (20, 2)
- 8.62 – 13.21
- in the lower half of the band · %B 0.11 · band width 42.1%
- SMA 50 / 200
- 11.86 / 8.61
- mixed trend
- MACD (12, 26, 9)
- -0.70 / -0.45
- MACD below signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −21.4% | −2.0% | −19.4 pp | — |
| 3 months | −22.9% | −2.2% | −20.8 pp | — |
| 6 months | +77.5% | +4.3% | +73.2 pp | — |
| Year to date | +142.4% | +10.6% | +131.9 pp | — |
| 1 year | +450.6% | +10.5% | +440.1 pp | +16.6% |
| 3 years | +852.1% | +73.7% | +778.4 pp | +16.8% |
| 5 years | −2.4% | +61.7% | −64.1 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Cost of revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 ≈ |
| SG&A | 3.0 m | 2.5 m | 2.9 m | 3.0 m | 2.9 m | 3.5 m | — | — |
| Operating income | -7.3 m | -6.9 m | -6.1 m | -6.9 m | -7.1 m | -8.3 m | -9.3 m | -10.6 m |
| Net income | -7.1 m | -6.7 m | -5.8 m | -6.6 m | -6.8 m | -7.7 m | -8.4 m | -9.6 m |
| Diluted EPS | -0.10 | -0.09 ≈ | -0.07 | -0.07 | -0.06 | -0.05 ≈ | -0.05 | -0.05 |
| Operating cash flow | -7.8 m ≈ | -7.2 m | -9.1 m | -7.3 m ≈ | -7.1 m ≈ | -4.9 m | -8.8 m | -7.6 m ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | unavailable | 0 | 1.9 m | 7.6 m | 1.0 m | 0 | unavailable | unavailable |
| Revenue YoY | unavailable | unavailable | unavailable | +300.0% | −86.8% | −100.0% | unavailable | unavailable |
| Net income | -27.7 m | -19.3 m | -16.8 m | -20.7 m | -41.3 m | -37.3 m | -30.9 m | -26.9 m |
| Net income YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | unavailable | unavailable | -2.11 | -1.34 | -2.13 | -1.34 | -0.50 | -0.25 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| net % | unavailable | unavailable | -881.9% | -272.4% | -4,130.1% | unavailable | unavailable | unavailable |
| Free cash flow | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 71.8 m USD
- Financial debt
- unavailable USD
- Net debt
- unavailable USD
- Equity
- 70.9 m USD
- Total assets
- 78.3 m USD
- Debt / equity
- unavailable
- Current ratio
- 10.72x
- ROE
- -66.9%
- ROA
- -54.9%
- FCF margin
- unavailable
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 1.9 m | 7.6 m | 1.0 m | 0 | — | — | SEC (XBRL)· 28 Mar 2024verified |
| Cost of revenue | 0 | 200.0 k | 100.0 k | 0 | 0 | 0 | SEC (XBRL)· 19 Mar 2026verified |
| Gross profit | 1.9 m ≈ | 7.4 m ≈ | 900.0 k ≈ | 0 ≈ | — | — | SEC (XBRL)· 28 Mar 2024derived |
| Research & development | 9.3 m | 15.7 m | — | — | — | — | SEC (XBRL)· 31 Mar 2022verified |
| SG&A | 9.6 m | 11.3 m | 12.6 m | 13.9 m | 12.4 m | 12.3 m | SEC (XBRL)· 19 Mar 2026verified |
| Operating income | -17.0 m | -25.3 m | -42.0 m | -37.9 m | -31.5 m | -28.3 m | SEC (XBRL)· 19 Mar 2026verified |
| Pre-tax income | -16.8 m | -20.9 m | -41.3 m | -37.3 m | -30.9 m | -26.9 m | SEC (XBRL)· 19 Mar 2026verified |
| Income tax | -17.0 k | -237.0 k | 0 | 0 | 0 | 0 | SEC (XBRL)· 19 Mar 2026verified |
| Net income | -16.8 m | -20.7 m | -41.3 m | -37.3 m | -30.9 m | -26.9 m | SEC (XBRL)· 19 Mar 2026verified |
| Diluted EPS | -2.11 | -1.34 | -2.13 | -1.34 | -0.50 | -0.25 | SEC (XBRL)· 19 Mar 2026verified |
| Weighted average diluted shares | 8.0 m | 15.5 m | 19.4 m | 27.8 m | 61.2 m | 109.1 m | SEC (XBRL)· 19 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Revenue − Cost of revenue.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 35.3 m | 21.4 m | 17.1 m | 2.5 m | 13.9 m | 71.8 m | SEC (XBRL)· 19 Mar 2026verified |
| Receivables | — | 0 | — | — | — | — | SEC (XBRL)· 12 May 2022verified |
| Current assets | 36.9 m | 23.0 m | 17.8 m | 3.2 m | 16.3 m | 75.2 m | SEC (XBRL)· 19 Mar 2026verified |
| Goodwill | 1.9 m | 1.9 m | 1.9 m | 1.9 m | 1.9 m | 1.9 m | SEC (XBRL)· 19 Mar 2026verified |
| Total assets | 46.0 m | 26.3 m | 20.9 m | 6.2 m | 19.4 m | 78.3 m | SEC (XBRL)· 19 Mar 2026verified |
| Accounts payable | 4.7 m | 2.1 m | 3.4 m | 5.6 m | 3.5 m | 2.9 m | SEC (XBRL)· 19 Mar 2026verified |
| Current liabilities | 12.3 m | 5.0 m | 15.5 m | 13.7 m | 9.5 m | 7.0 m | SEC (XBRL)· 19 Mar 2026verified |
| Total liabilities | 18.1 m | 5.9 m | 16.1 m | 14.2 m | 10.0 m | 7.5 m | SEC (XBRL)· 19 Mar 2026verified |
| Equity | 28.0 m † | 20.3 m † | 4.9 m † | -8.0 m † | 9.5 m † | 70.9 m † | SEC (XBRL)· 19 Mar 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -10.4 m | -26.0 m | -23.8 m | -31.4 m | -35.4 m | -28.4 m | SEC (XBRL)· 19 Mar 2026verified |
| Investing cash flow | — | 0 | -4.5 m | -5.5 m | 0 | — | SEC (XBRL)· 20 Mar 2025verified |
| Financing cash flow | 38.4 m | 12.1 m | 24.1 m | 22.3 m | 46.8 m | 86.3 m | SEC (XBRL)· 19 Mar 2026verified |
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 1 of at least 6
- score weight coverage: 4.2% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 1.8 bn USD
Key indicators
Coverage and freshness
Score by group
4% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · the input exists, but its latest figure is far older than the latest reported period: not used
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · input data missing
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 1 of at least 6; score weight coverage: 4.2% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | unavailable | unavailable | — |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | unavailable | unavailable | — |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | unavailable | unavailable | — |
| Current ratio · Balance sheet | 18.8x | 100 (on a fixed band) | 100% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | unavailable | unavailable | — |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet· partial100/100 · 1/3 factors with a value
- Growth· partialunavailable · 0/2 factors with a value
- Quality· partialunavailable · 0/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partialunavailable · 0/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
SELLAS Life Sciences Group, Inc. (SLS). Latest full fiscal year: 2023; data up to 2026-06-30.
Figures computed from the financial statements: revenue 0 USD in 2023; YoY growth -100.0%; ROE -39.6%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 1 of at least 6; score weight coverage: 4.2% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Current ratio: 18.8x
What contradicts it
No signal among the computed factors. That is not an absence of risk: factors without data were not assessed, and business risks (margins, inventory, demand) are in the source-based analysis.
Not assessed (insufficient data or a ratio without meaning): ROIC, Net margin, FCF conversion, Revenue CAGR 3Y, EPS CAGR 3Y, Net debt / EBITDA, Interest coverage, P/E (TTM), EV/EBITDA, FCF yield, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Pharmaceutical Preparations (SIC 2834) · same industry (4-digit SIC) · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| LLYEli Lilly And Company | 1,325.9 bn | 45.7 | 86.1% | 31.9% | +44.7% | +31% / +138% |
| JNJJohnson & Johnson | 640.8 bn | 40.4 | 20.0% | 16.2% | +6.0% | +29% / +72% |
| ONCBeone Medicines Ltd. | 524.7 bn | 817.5 | 14.7% | 10.7% | +40.2% | +4% / +90% |
| ABBVAbbVie Inc. | 505.5 bn | 49.2 | — | 15.7% | +8.6% | +26% / +101% |
| MRKMerck & Co., Inc. | 356.9 bn | 115.6 | 7.0% | 4.8% | +1.3% | +38% / +41% |
| ABTAbbott Laboratories | 190.6 bn | 30.6 | 12.4% | 13.9% | +5.7% | −15% / +5% |
| PFEPfizer Inc | 171.0 bn | 42.7 | 4.4% | 6.3% | −1.6% | +17% / −2% |
| VRTXVertex Pharmaceuticals Inc | 134.6 bn | 34.2 | 20.8% | 30.7% | +8.9% | +22% / +50% |
| BMYBristol-Myers Squibb Company | 126.1 bn | 13.7 | 44.1% | 18.5% | −0.2% | +25% / +25% |
| TEVATeva Pharmaceutical Industries Limited | 48.9 bn | 97.6 | 6.6% | 3.6% | +4.3% | +56% / +327% |
| ZTSZoetis Inc. | 34.3 bn | 13.7 | 64.4% | 27.5% | +2.3% | −35% / −53% |
| ROIVRoivant Sciences Ltd. | 26.0 bn | — | -6.2% | -3,535.0% | −71.6% | +73% / +277% |
| UTHRUnited Therapeutics Corporation | 25.8 bn | 21.5 | 19.3% | 41.6% | +10.6% | +24% / +151% |
| RPRXRoyalty Pharma plc | 25.8 bn | 37.6 | 8.5% | 32.1% | +5.1% | +66% / +145% |
| INSMInsmed Inc | 22.9 bn | — | -72.5% | -39.9% | +66.7% | −50% / +317% |
| VTRSViatris Inc. | 21.7 bn | — | -23.6% | -23.9% | −3.0% | +77% / +106% |
| ALNYAlnylam Pharmaceuticals, Inc. | 21.4 bn | 8.1 | 126.6% | 52.8% | +65.2% | −65% / −5% |
| TGTXTg Therapeutics, Inc. | 9.4 bn | 22.5 | 100.3% | 55.2% | +87.3% | +85% / +381% |
| BLRXBioLineRx Ltd | 4.9 bn | — | -12.8% | -171.7% | −95.9% | −46% / −97% |
| BHCBausch Health Companies Inc. | 3.1 bn | — | — | -7.6% | +6.7% | +31% / +17% |
| SLSSELLAS Life Sciences Group, Inc. | 1.8 bn | — | -39.6% | — | −100.0% | +451% / +852% |
| ANABAnaptysbio, Inc. | 1.4 bn | 11.5 | — | 82.4% | +157.0% | +71% / +404% |
| KURAKura Oncology, Inc. | 677.0 m | — | -167.7% | -384.3% | +25.2% | −37% / −21% |
| DMACDiaMedica Therapeutics Inc. | 580.8 m | — | -114.6% | — | unavailable | +25% / +341% |
| PHATPhathom Pharmaceuticals, Inc. | 461.7 m | — | — | -30.2% | +216.9% | −64% / −19% |
1- and 3-year price returns: for SLS from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Scenarios are not available. input data missing
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
SELLAS Life Sciences Group is a late-stage biopharmaceutical company developing the GPS immunotherapy and the CDK9 inhibitor SLS009 for cancer, mainly acute myeloid leukemia. The company faces two key moments: the final analysis of the Phase 3 REGAL trial, triggered by the 80th event, and topline data from the Phase 2 SLS009 study, expected in the fourth quarter of 2026. As of June 30, 2026 it reported cash of $138.3 million 3.
SWOT
Strengths
- The company has two candidates in advanced clinical studies and multiple regulatory designations, including orphan and Fast Track 1.
- SLS009 Phase 2 results met all primary endpoints, and the FDA recommended extending the study to first-line AML 1.
- Cash available at June 30, 2026 rose significantly from the prior year end, which supports continued programs 3.
Weaknesses
- The company has no approved products and no product revenue, and losses have grown over time 13.
- Dependence on a single pivotal study, REGAL, makes success hinge on an event-driven outcome that is hard to anticipate 1.
- Operating expenses have risen as the company prepares for a possible license application, and new equity issuance could dilute shareholders 13.
Opportunities
- A favorable REGAL result could open the path to a biologics license application for GPS in AML 13.
- Preclinical data in pancreatic cancer resistant to RAS inhibitors could extend SLS009 into solid tumors 3.
- The IMPACT-AML collaboration gives access to multiple European clinical sites, which could speed enrollment 1.
Threats
- The final analysis depends on the number of deaths, and its timing may differ from current expectations 1.
- An arbitration dispute with the Chinese partner over milestone payments could affect future receipts 1.
- Competition in CDK9 inhibitors and WT1 immunotherapies could reduce potential share if rivals reach the market first 1.
Risks
- REGAL trial outcomehigh
The final analysis of the Phase 3 study is decisive for GPS, and an unfavorable result could halt the program 12.
- Need for additional financinghigh
The company expects rising expenses and may need new capital, which could dilute existing shareholders 13.
- Dispute with the Chinese partnermedium
The arbitration with 3D Medicines over milestone payments could delay or reduce receipts from the Greater China license 1.
- Clinical timeline uncertaintymedium
SLS009 results are expected in the fourth quarter of 2026, but delays could change the development plan 23.
- Regulatory approval riskmedium
Even with favorable designations, approval is not assured, and FDA requirements could change timing or the content of filings 1.
Investment thesis
What would need to be true (bull case)
- If the REGAL analysis confirms a survival benefit, GPS could become a maintenance option for AML patients in complete remission 1.
- SLS009 results in relapsed and refractory disease, with median survival above historical benchmarks, could support a first-line program 1.
- Extension into pancreatic cancer could add a new direction if preclinical data hold up in clinical studies 3.
What would break the thesis
- With no approved products and no revenue, the company's value rests entirely on clinical results that are not yet confirmed 1.
- The need for funding could lead to significant dilution for shareholders if studies are delayed or fail 13.
- The dispute with the Chinese partner and uncertainty over the event count could extend the timeline and reduce predictability 12.
What to watch
- Reaching the 80th event in the REGAL study and announcement of the final analysisnext 10-Q
- Topline data from the first-line Phase 2 SLS009 study in AMLQ4 2026
- Trend in R&D and G&A spending and the need for additional capitalQ3 2026
- Outcome of the arbitration with 3D Medicines over milestone payments2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
SELLAS is a late-stage clinical biopharmaceutical company focused on novel therapies for a broad range of cancer indications 1. It has no approved products and has not generated product revenue to date, and it has incurred operating losses in every reporting period since inception 1. Its strategy is to develop several oncology candidates, with acute myeloid leukemia as the lead indication for both GPS and SLS009 1.
The lead candidate, galinpepimut-S (GPS), is a peptide immunotherapy targeting the WT1 antigen, licensed from Memorial Sloan Kettering Cancer Center 1. The Phase 3 REGAL study evaluates GPS monotherapy in AML patients in maintenance after second complete remission, with overall survival as the primary endpoint 1. The company says final results will follow the 80th event, after which a Biologics License Application could be considered 23.
The second candidate, SLS009 (tambiciclib), is a highly selective CDK9 inhibitor licensed from GenFleet for all uses worldwide outside Greater China 1. In the relapsed or refractory Phase 2 study, the overall response rate was 33% across all cohorts 1. The first-line Phase 2 study had 28 patients enrolled as of August 10, 2026, with topline data expected in the fourth quarter of 2026 23.
Segments
GPS (galinpepimut-S)
GPS is the company's core immunotherapy, with the Phase 3 REGAL study in AML as the main driver of value. The pooled event count reached 78 as of May 11, 2026, and the final analysis will follow the 80th event 2. The China license with 3D Medicines includes payments already received and future milestones that remain in arbitration 1.
SLS009 (tambiciclib)
SLS009 is the second clinical program, with a selectivity profile that could reduce toxicity compared with older CDK9 inhibitors 1. The first-line Phase 2 study is ongoing, and the company has extended European access through the IMPACT-AML network 12. Recent preclinical data suggest activity in pancreatic cancer resistant to RAS inhibitors 3.
Market context
The target market is oncology therapies for AML and other hematologic and solid cancers, where WT1 is overexpressed in many tumor types 1. The size of the market and reimbursement prospects are not quantified in the sources and depend on study results and future approvals 1.
Market access depends on regulatory approvals in each territory, accepted prices and reimbursement by third-party payors, factors the company describes as uncertain 1. With no product revenue yet, any sales estimate remains hypothetical 1.
Trends
- Progress of REGAL eventsmixed
The event count needed for the final analysis is advancing, which could accelerate the path to a possible license application if results are favorable 23. The exact timing is hard to predict because the analysis is event driven 1.
- Regulatory acceleration designationstailwind
GPS and SLS009 have received orphan, Fast Track and rare pediatric disease designations, which could ease development and review 1. These do not guarantee approval but may shorten certain steps 1.
- High capital needsheadwind
The company expects growing losses as trial and manufacturing costs rise, and additional financing could be needed if results are delayed 1. Higher R&D spending in the first half of 2026 points the same way 3.
- Interest in AML with adverse mutationstailwind
Data on ASXL1 mutation and other molecular profiles suggest a niche of patients with poor prognosis where new therapies could have impact 13. This scientific interest may support academic collaborations but remains at an early or preclinical stage 3.
Competitive position
The sources do not describe direct competitors by name, but they reference AML standards of care, such as the venetoclax and azacitidine combination, as the comparison point for SLS009 1. Competition also extends to next-generation CDK9 inhibitors in clinical development 1.
In WT1 immunotherapy and CDK9 inhibition, the sources indicate several developers in clinical studies, and SLS009's differentiation rests on selectivity and reduced toxicity 1. Relative positioning will depend on future data from ongoing studies 1.
- Other next-generation CDK9 inhibitors
Cited in the source as in clinical development, without named identification in the analyzed texts.
- Venetoclax and azacitidine standard therapy
Reference treatment in AML, to which SLS009 is added in the Phase 2 study 1.
- Best available treatment (BAT)
Comparator arm of the REGAL study, chosen by investigators under local practice 1.
- Developers of WT1 immunotherapies and peptide vaccines
Candidates in clinical studies for hematologic and solid indications, identified generically in the source 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- STAT+: A Sellas immunotherapy study, long delayed, will end in failureSTAT News · 17 Sept 2026 · EN
- Why Analysts Think Sellas Life Sciences Stock Can Gain 150% From HereYahoo Finance — News · 01 Sept 2026 · EN
- Sellas Life (SLS) Falls 13% as Firm Still Mum on ALM Drug CandidateYahoo Finance — News · 29 Aug 2026 · EN
SEC filings
- Current report11 Aug 2026Results of operations · Financial statements and exhibits
- Quarterly report11 Aug 2026
- Current report27 Jul 2026Results of operations · Other events · Financial statements and exhibits
- Current report25 Jun 2026Departure or appointment of officers · Financial statements and exhibits
- Current report18 Jun 2026Shareholder vote
- Current report02 Jun 2026Other events · Financial statements and exhibits
- Current report12 May 2026Results of operations · Financial statements and exhibits
- Quarterly report12 May 2026
- Proxy statement23 Apr 2026
- Current report19 Mar 2026Results of operations · Financial statements and exhibits
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / SELLAS Life Sciences Group, Inc. · 19 Mar 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / SELLAS Life Sciences Group, Inc. · 11 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / SELLAS Life Sciences Group, Inc. · 11 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.